Table 4.
Required accumulation levels of ICIs in plants to achieve a breakeven situation with mammalian cell‐derived counterparts. Projections based on 2021 sales prices of ICIs Pembrolizumab £26 300 g−1 (~€31 600 g−1) and Nivolumab $28 895 g−1 (~€25 500 g−1)
| Antibody | Pembrolizumab | Nivolumab | ||
|---|---|---|---|---|
| Scenario (production costs as per cent 2021 sales price) | 10% (€12 000 g−1) | 5% (€6000 g−1) | 10% (€5000 g−1) | 5% (€2500 g−1) |
| Required accumulation (g/kg LFW) | ||||
| Manual/transgenic (low income, 6000 plants per batch) | 0.23 | 0.52 | 0.66 | 2.21 |
| Automated/transient (high income, 6000 plants per batch) | 0.28 | 0.63 | 0.80 | 2.23 |